Takeda Terminates DNL593 Collaboration; Denali Regains Full Rights to FTD-GRN Program
Summary
Denali Therapeutics announced Takeda's termination of their DNL593 collaboration, with Denali regaining full rights to the investigational FTD-GRN therapy and committing to continue its development.
Key Events
-
Collaboration Agreement Terminated
Takeda Pharmaceutical Company Limited terminated the co-development and co-commercialization agreement for DNL593 (PTV:PGRN), effective 60 days from April 3, 2026.
-
Denali Regains Full Rights
All rights to the DNL593 program, an investigational therapy for GRN-related Frontotemporal Dementia (FTD-GRN), will revert to Denali Therapeutics.
-
Development to Continue Independently
Denali plans to continue the clinical development of DNL593, with results from the ongoing Phase 1/2 study expected by the end of 2026. The termination was for strategic reasons, not efficacy or safety.
Analysis
This 8-K confirms the termination of the co-development and co-commercialization agreement with Takeda for DNL593, an investigational therapy for Frontotemporal Dementia. While the termination is not related to efficacy or safety, it means Denali will now bear the full development costs and risks for the program. The company plans to continue the Phase 1/2 study, with results expected by the end of 2026. This event follows recent positive news of FDA approval for AVLAYAH™ and a $200 million royalty funding agreement, providing some financial cushion. Investors should monitor Denali's progress with DNL593 independently and any potential future partnership discussions.
At the time of this filing, DNLI was trading at $20.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $10.57 to $23.77. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.